Related Experiment Video
Updated: Jul 17, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
Published on: October 5, 2012
Small-molecule inhibitors of Bcl-2
Michael K Manion1, John Fry, Pam S Schwartz
1Fred Hutchinson Cancer Research Center, Division of Clinical Research and Human Biology, 1100 Fairview Avenue North, C3-168, Seattle, WA 98109-1024, USA.
Abstract:
Cancer cells with elevated levels of Bcl-2 and the related anti-apoptotic proteins Bcl-x(L), Mcl-1 and Bcl-W are broadly resistant to standard anticancer drugs and other therapeutic modalities. Antisense oligodeoxynucleotides and, more recently, small-molecule ligands for Bcl-2 and Bcl-x(L), sensitize cancer cells to cytotoxic therapies. In some cases, Bcl-2-targeted therapies can function as single therapeutic agents to kill tumor cells, suggesting that Bcl-2 has an important role in the critical functions of cancer cells. The molecular mechanisms of Bcl-2 are not completely understood, therefore, the validation of cytotoxic mechanisms related to Bcl-2 as well as the identification of surrogate markers for Bcl-2 function are significant obstacles for drug development. Despite these problems, two Bcl-2 small-molecule inhibitors are currently undergoing phase I/II clinical trials and several other compounds are in preclinical development. Ongoing studies with these investigational drugs should provide new insights into optimal strategies to disrupt Bcl-2 survival functions to selectively kill cancer cells.
Related Concept Videos
The Intrinsic Apoptotic Pathway
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity
Inhibition of CDK Activity
Inhibitors of Bacterial DNA Synthesis
Inhibitors of Bacterial Protein Synthesis

